Crossmark

Pharmaceutical Co-crystal of Antiviral Agent Efavirenz with Nicotinamide for the Enhancement of Solubility, Physicochemical Stability, and Oral Bioavailability

Crossref DOI link: https://doi.org/10.1208/s12249-022-02467-7

Published Online: 2022-11-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yadav, Dattatraya

Savjani, Jignasa

Savjani, Ketan

Kumar, Aakash

Patel, Snehal
License Information

Text and Data Mining valid from 2022-11-29

Version of Record valid from 2022-11-29
More Information

Article History

Received: 21 June 2022

Accepted: 9 November 2022

First Online: 29 November 2022

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below